Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699. https://doi.org/10.1016/s0140-6736(17)30933-9

Article  PubMed  Google Scholar 

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M (2018) Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open 4(Suppl 1):e000782. https://doi.org/10.1136/rmdopen-2018-000782

Article  PubMed  PubMed Central  Google Scholar 

Seibold JR (2001) Clinical trials: types, design, and end-points. Curr Opin Rheumatol 13(6):512–515. https://doi.org/10.1097/00002281-200111000-00011

Article  CAS  PubMed  Google Scholar 

Silver RM, Metcalf JF, LeRoy EC (1986) Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum 29(4):525–531. https://doi.org/10.1002/art.1780290410

Article  CAS  PubMed  Google Scholar 

Cutolo M, Ruaro B, Montagna P, Brizzolara R, Stratta E, Trombetta AC, Scabini S, Tavilla PP, Parodi A, Corallo C, Giordano N, Paolino S, Pizzorni C, Sulli A, Smith V, Soldano S (2018) Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. Arthritis Res Ther 20(1):77. https://doi.org/10.1186/s13075-018-1577-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality**dedicated to the memory of E. Carwile LeRoy, 1933–2002. Rheumatology (Oxford) 44(10):1212–1216. https://doi.org/10.1093/rheumatology/keh671

Article  CAS  PubMed  Google Scholar 

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr., Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205

CAS  PubMed  Google Scholar 

Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castañeda AR, Rodríguez-Reyna TS (2019) Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Biomed Res Int 2019:4569826. https://doi.org/10.1155/2019/4569826

Article  CAS  PubMed  PubMed Central  Google Scholar 

Denton CP, Murray C (2019) Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis. Arthritis Res Ther 21(1):81. https://doi.org/10.1186/s13075-019-1872-4

Article  PubMed  PubMed Central  Google Scholar 

Brown M, O’Reilly S (2019) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol 195(3):310–321. https://doi.org/10.1111/cei.13238

Article  CAS  PubMed  Google Scholar 

Rubio-Rivas M, Corbella X, Guillén-Del-Castillo A, Tolosa Vilella C, Colunga Argüelles D, Argibay A, Vargas Hitos JA, Todolí Parra JA, González-Echávarri C, Ortego-Centeno N, Trapiella Martínez L, Rodríguez Carballeira M, Marín Ballvé A, Pla Salas X, Perales Fraile I, Chamorro AJ, Madroñero Vuelta AB, Freire M, Ruiz Muñoz M, González García A, Pons Martín Del Campo I, Sánchez García ME, Bernal Bello D, Espinosa G, García Hernández FJ, Sáez Comet L, Ríos Blanco JJ, Fernández de la Puebla Giménez R, Sánchez Trigo S, Fonollosa Pla V, Simeón Aznar CP (2020) Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: derivation and internal validation. Autoimmun Rev 19(5):102507. https://doi.org/10.1016/j.autrev.2020.102507

Article  PubMed  Google Scholar 

Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E (2019) Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis. Arthritis Rheumatol 71(9):1553–1570. https://doi.org/10.1002/art.40906

Article  PubMed  PubMed Central  Google Scholar 

Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O (2021) Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res. https://doi.org/10.1183/23120541.00235-2020

Article  PubMed  PubMed Central  Google Scholar 

Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, de Pena O, Yao J, Kramer Z, Distler F O (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79(5):618–625. https://doi.org/10.1136/annrheumdis-2019-216823

Article  PubMed  PubMed Central  Google Scholar 

Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B (2020) Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol 72(8):1350–1360. https://doi.org/10.1002/art.41294

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 75(9):1608–1618. https://doi.org/10.1002/art.42510

Article  CAS  PubMed  Google Scholar 

Allanore Y, Wung P, Soubrane C, Esperet C, Marrache F, Bejuit R, Lahmar A, Khanna D, Denton CP (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79(12):1600–1607. https://doi.org/10.1136/annrheumdis-2020-218447

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963–974. https://doi.org/10.1016/s2213-2600(20)30318-0

Article  CAS  PubMed  Google Scholar 

Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2019) Comment on: intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply. Rheumatology (Oxford) 58(5):925–926. https://doi.org/10.1093/rheumatology/kez054

Article  PubMed  Google Scholar 

Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, Suliman YA, Matucci-Cerinic M, Gabrielli A, Distler O, Hoffmann-Vold AM, Castellví I, Balbir-Gurman A, Vonk M, Ananyeva L, Rednic S, Tarasova A, Ostojic P, Boyadzhieva V, El Aoufy K, Farrington S, Galetti I, Denton CP, Kowal-Bielecka O, Mueller-Ladner U, Allanore Y (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29–40. https://doi.org/10.1136/ard-2024-226430

Article  CAS  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/m14-2385

Article  PubMed  Google Scholar 

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S (2023) A 24-week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 75(8):1434–1444. https://doi.org/10.1002/art.42477

Article  CAS  PubMed  Google Scholar 

National Heart L, and Blood Institute (2013) Quality Assessment Tool for Controlled Intervention Studies. In: ed. National Institutes of Health

Griffiths-Jones DJ, Garcia YS, Ryder WD, Pauling JD, Hall F, Lanyon P, Bhat S, Douglas K, Gunawardena H, Akil M, Anderson M, Griffiths B, Del Galdo F, Youssef H, Madhok R, Arthurs B, Buch M, Fligelstone K, Zubair M, Mason JC, Denton CP, Herrick AL (2023) A phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology (Oxford) 62(9):3133–3138. https://doi.org/10.1093/rheumatology/kead012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP (2022) Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med 205(6):674–684. https://doi.org/10.1164/r